EQS-Adhoc: Viromed Medical AG: Study on cold plasma application in the lung accepted for publication by an internationally leading medical journal
|
EQS-Ad-hoc: Viromed Medical AG / Key word(s): Other Viromed Medical AG: Study on cold plasma application in the lung accepted for publication by an internationally leading medical journal Rellingen, 30 September 2026 – Viromed Medical AG (“Viromed”; ISIN: DE000A40ZVN7) announces that a scientific paper on the results of the study on the application of cold atmospheric plasma in the lung has cleared this high hurdle and has been accepted by an internationally leading medical journal. Viromed was informed of this by the scientific leadership of the study. The study was prepared and submitted under the scientific leadership of Prof. Dr. Hortense Slevogt, Hannover Medical School and Helmholtz Centre for Infection Research. Uwe Perbandt, CEO of Viromed Medical AG, is a co-author of the paper. The study addresses the application of cold atmospheric plasma in severe infectious lung diseases, in particular in connection with ventilator-associated pneumonia. A significant, pathogen-independent reduction of pathogenic germs was demonstrated, together with a clearly defined therapeutic safety window. Histological analyses and further examinations showed no safety-relevant tissue damage within this application window. The scientific details of the study will be communicated by the participating scientists after publication of the paper. Notifying person: Uwe Perbandt, CEO of Viromed Medical AG Contact Viromed: E-mail: kontakt@viromed-medical.de End of Inside Information
30-Sep-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Viromed Medical AG |
| Hauptstraße 105 | |
| 25462 Rellingen | |
| Germany | |
| E-mail: | kontakt@viromed-medical.de |
| Internet: | https://www.viromed-medical-ag.de/ |
| ISIN: | DE000A40ZVN7 |
| WKN: | A40ZVN |
| Listed: | Regulated Unofficial Market in Dusseldorf, Frankfurt, Hamburg, Tradegate BSX |
| LEI Code: | 894500XR05MYCVCCR171 |
| EQS News ID: | 2408210 |
| End of Announcement | EQS News Service |
|
|
2408210 30-Sep-2026 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | ||
| Sales1 | 0,00 | 0,00 | 0,00 | 0,00 | 1,13 | 5,09 | 8,50 | |
| EBITDA1,2 | 0,00 | 0,00 | 0,00 | -0,11 | 4,98 | 2,25 | 0,00 | |
| EBITDA-Margin3 | 0,00 | 0,00 | 0,00 | 0,00 | 442,93 | 44,25 | 0,00 | |
| EBIT1,4 | 0,00 | 0,00 | 0,00 | -0,11 | 4,73 | 1,73 | 8,00 | |
| EBIT-Margin5 | 0,00 | 0,00 | 0,00 | 0,00 | 420,44 | 33,95 | 94,12 | |
| Net Profit (Loss)1 | 0,00 | 0,00 | 0,00 | -0,11 | -3,09 | 0,60 | 0,00 | |
| Net-Margin6 | 0,00 | 0,00 | 0,00 | 0,00 | -274,84 | 11,87 | 0,00 | |
| Cashflow1,7 | 0,00 | 0,00 | 0,00 | -0,11 | -2,84 | 1,13 | 0,00 | |
| Earnings per share8 | 0,00 | 1,23 | -0,01 | -0,01 | -0,15 | 0,03 | -0,01 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Bernd Lenzen
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Viromed Medical | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A40ZVN | DE000A40ZVN7 | AG | 102,42 Mio € | 04.05.2022 | 9F5FMR3F+R3 | |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 59,00 | 0,00 | 0,00 | 236,00 | 10,78 | 90,80 | 20,13 |
|
Dividend '2024 in € |
Dividend '2025 in € |
Dividend '2026e in € |
Div.-Yield '2026e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 06.07.2026 | 28.09.2026 | 22.05.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -19,92% | -25,81% | +24,21% | +45,68% | -1,67% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
